1-(7,8-dihydro-6H-pyrido[3,4-b]pyrrolizin-5-yl)propan-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 1-(7,8-dihydro-6H-pyrido[3,4-b]pyrrolizin-5-yl)propan-2-amine
• 化学式: C₁₃H₁₇N₃
• 分子量: 215.29
• InChiKey: HVHVXSNVYIVPKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Aza- indolyl derivatives for treating obesity
  申请人：——

  公开号：US20010025039A1

  公开（公告）日：2001-09-27

  Novel compounds of formula (I): 1 wherein X 1 , X 2 , X 3 and X 4 , n, R 1 , R 2 and R 3 are defined in the specification, and pharmaceutically acceptable salts and prodrugs of the compounds of formula (I) have therapeutic uses. These compounds are useful for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea. They are particularly useful for the treatment of obesity.

  式(I)的新化合物：其中X1、X2、X3和X4、n、R1、R2和R3在规范中有定义，化合物的药物可接受的盐和前药具有治疗用途。这些化合物对于治疗中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠道疾病、尿崩症和睡眠呼吸暂停症等疾病有用。它们特别适用于肥胖症的治疗。
• FUSED HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：SHIRAI Junya

  公开号：US20120165312A1

  公开（公告）日：2012-06-28

  The present invention relates to a serotonin 5-HT 2C receptor activator containing a compound represented by the formula wherein ring A is a 5- or 6-membered aromatic heterocycle optionally having substituent(s), and ring B is a 7- to 9-membered ring optionally having substituent(s) other than an oxo group wherein the combination of m and n (m,n) is (1,2), (2,1), (2,2), (3,1), (3,2) or (4,1), or a salt thereof or a prodrug thereof, and a fused heterocyclic compound having a serotonin 5-HT 2C receptor activating action and the like.

  本发明涉及一种含有由以下式表示的化合物的血清素5-HT2C受体激动剂： 其中环A是一种5-或6-成员芳香杂环，可选地具有取代基，环B是一种7-至9-成员环，除了一个氧代基外还可选地具有取代基，其中m和n（m，n）的组合为（1，2），（2，1），（2，2），（3，1），（3，2）或（4，1），或其盐或前药，以及具有血清素5-HT2C受体激活作用的融合杂环化合物等。
• CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF
  申请人：Matsumoto Takahiro

  公开号：US20100266504A1

  公开（公告）日：2010-10-21

  Provided are a condensed pyridine derivative having a serotonin 5-HT 2C receptor activation action, a prophylactic or therapeutic agent for a lower urinary tract symptom, obesity and/or organ prolapse and the like containing the condensed pyridine derivative, a screening method for a substance that increases leak point pressure upon a rise in the intravesical pressure or a prophylactic or therapeutic drug for stress urinary incontinence, a prophylactic or therapeutic drug for cystoceles or enteroceles, containing a substance that activates serotonin 5-HT 2C receptor, and a method of screening for a therapeutic drug for cystoceles or enteroceles, including increasing an intravesical pressure after bilateral transection of the hypogastric nerve and pudendal nerve of an animal, and measuring a closure response in the urethra, the rectum or the vagina observed at that time. A serotonin 5-HT 2c receptor activator containing a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

  提供了一种具有血清素5-HT2C受体激活作用的缩合吡啶衍生物，以及包含该缩合吡啶衍生物的预防或治疗下尿路症状、肥胖和/或器官脱垂等药物，以及增加膀胱内压力时增加泄漏点压力或预防或治疗压力性尿失禁的药物筛选方法，包含激活血清素5-HT2C受体的物质的预防或治疗膀胱脱垂或肠脱垂的药物，以及通过双侧切断动物的会阴神经和耻骨神经后增加膀胱内压力并测量尿道、直肠或阴道在此时观察到的闭合反应的膀胱脱垂或肠脱垂的治疗药物筛选方法。其中包含式的化合物的血清素5-HT2C受体激活剂：式中每个符号如规范中定义的那样，或其盐。
• New aza-indolyl derivatives for the treatment of obesity
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1132389A1

  公开（公告）日：2001-09-12

  The present invention refers to chemical compounds of formula (I); wherein X1, X2, X3 and X4, n, R1, R2 and R3 and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

  本发明涉及式（I）化合物； 其中X1、X2、X3和X4、n、R1、R2和R3及其药学上可接受的盐和原药，以及它们在治疗中的用途，特别是用于治疗中枢神经系统疾病；中枢神经系统损伤；心血管疾病；胃肠道疾病；糖尿病和睡眠呼吸暂停，尤其是用于治疗肥胖症。
• PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1792629A1

  公开（公告）日：2007-06-06

  An agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that activates a serotonin 5-HT2C receptor, an agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that stimulates an androgen binding site, and a method of screening for a drug for the prophylaxis or treatment of abdominal pressure incontinence, which includes electrostimulating the abdominal muscles or a nerve controlling them of an animal to increase the abdominal pressure, and measuring the leak point pressure at that time.

  一种预防或治疗压力性尿失禁的药物，其中含有一种能激活5-羟色胺5-HT2C受体的物质；一种预防或治疗压力性尿失禁的药物，其中含有一种能刺激雄激素结合位点的物质、以及一种筛选预防或治疗腹压性尿失禁药物的方法，其中包括电刺激动物的腹部肌肉或控制腹部肌肉的神经以增加腹压，并测量当时的漏点压力。